Search results
Serological tests for specific antibodies against SARS-CoV-2, including immunoglobulin M (IgM), IgG and IgA antibodies, have been developed as supplementary diagnostic methods as they can provide information about recent or prior infection (Peeling et al., 2020).
1 lip 2023 · The seroprevalence of SARS-CoV-2 IgM and IgG in COVID-19 patients was 81 and 83% less than 7 days after symptom onset, both antibodies raised to 95% at 2 weeks. Approximately 8% of COVID-19 patients tested negative for IgM or IgG .
The VivaDiag COVID-19 IgM/IgG rapid test determines COVID-19’s IgM and IgG antibodies, qualitatively. The manufacturer suggested that clinical findings should also be considered when the test result is interpreted.
29 kwi 2020 · We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG)....
13 lis 2020 · IgM and IgG were monitored dynamically for 16 patients with COVID‐19, the results showed that serological transformation of IgM was carried out simultaneously with IgG in seven patients, which was earlier than IgG in four patients and later than IgG in five patients.
28 maj 2020 · Serum IgM and IgG levels in moderate and severe COVID-19 patients were significantly higher than mild cases, while no significant difference was observed between severe and moderate patients...
17 lut 2021 · We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibodies in COVID-19 patients and the association between clinical classification and antibodies, which will contribute to the interpretation of IgM and IgG SARS-CoV-2 antibody tests and in predicting the outcomes of patients with COVID-19.
